Fmoc-Val-Cit-PAB-DuocarmycinTM is a drug-linker conjugate designed for antibody-drug conjugation (ADC), utilizing the antitumor antibiotic DuocarmycinTM. It is connected through the linker Fmoc-Val-Cit-PAB.
MAL-di-EG-Val-Cit-PAB-MMAE comprises the linker MAL-di-EG-Val-Cit-PAB and the potent tubulin inhibitor MMAE, which are essential components of antibody-drug conjugates (ADCs).
MC-Val-Cit-PAB-carfilzomib is a potent antitumor drug-linker conjugate for antibody-drug conjugates (ADC), comprising the irreversible proteasome inhibitor carfilzomib, connected through the ADC linker MC-Val-Cit-PAB.
MC-Val-Cit-PAB-Indibulin is an antitumor drug-linker conjugate for antibody-drug conjugates (ADCs), featuring the orally active tubulin assembly inhibitor, Indibulin, connected through the MC-Val-Cit-PAB ADC linker. This compound exhibits potent antitumor activity.
MC-Val-Cit-PAB-MMAF is an antibody-drug conjugate (ADC) component that exhibits antitumor properties through the action of the tubulin inhibitor, monomethyl auristatin F (MMAF), which is connected by a cathepsin-cleavable linker, MC-Val-Cit-PAB.
BCN-PEG3-Val-Cit is a PEG-based linker commonly employed in PROTAC synthesis[1]. Additionally, it serves as a cleavable 3 unit PEG linker in the production of antibody-drug conjugates (ADCs)[2].
Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) is a drug-linker conjugate for antibody-drug conjugates (ADCs) that combines the ADC linker (Acetylene-linker-Val-Cit-PABC) with the potent tubulin inhibitor MMAE.
Mal-PEG4-VC-PAB-DMEA-Seco-Duocarmycin SA is an antibody-drug conjugate linker that incorporates the antitumor antibiotic Duocarmycin SA, connected through the Mal-PEG4-VC-PAB-DMEA-Seco linker, for targeted cancer therapy.
mDPR(Boc)-Val-Cit-PAB is a cleavable linker employed in antibody-drug conjugates (ADCs) [1]. This chemical compound serves as a reliable linker in the formation of ADCs, which are biopharmaceuticals that combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs for targeted cancer therapy [1].
MC-Val-Cit-PAB-duocarmycin is an antibody-drug conjugate (ADC) linker that combines duocarmycin, a potent DNA minor groove-binding alkylating agent, with an antitumor drug through the MC-Val-Cit-PAB linker, exhibiting significant antitumor activity.
MC-Val-Cit-PAB-clindamycin is an antibody-drug conjugate (ADC) linker that combines the potent antitumor properties of clindamycin, a protein synthesis inhibitor, with the ADC linker MC-Val-Cit-PAB, to enhance its ability to target and kill cancer cells effectively.
Vat-Cit-PAB-Monomethyl Dolastatin 10 is an ADC linker-conjugated drug designed to deliver potent antitumor activity. It achieves this through Monomethyl Dolastatin 10, a potent tubulin inhibitor, connected via the Vat-Cit-PAB ADC linker.
Mal-amido-PEG2-Val-Cit-PAB-PNP is a cleavable 2-unit polyethylene glycol (PEG) based ADC linker utilized in the construction of antibody-drug conjugates (ADCs)[1].
Mal-Phe-C4-Val-Cit-PAB is a cleavable antibody-drug conjugate (ADC) linker featuring a Maleimide functional group. It is employed in the synthesis of ADCs.
SuO-Val-Cit-PAB-MMAE is an ADC (antibody-drug conjugate) linker comprising the anti-mitotic monomethyl auristatin E (MMAE, a tubulin inhibitor) connected through the SuO-Val-Cit-PAB peptide.
MC-Val-Cit-PAB-dimethylDNA31 is a drug-linker conjugate employed in antibody-drug conjugates (ADCs) that exhibits robust antitumor efficacy. This conjugate utilizes the ADC linker, MC-Val-Cit-PAB, to link to the potent antitumor agent dimethylDNA31. Notably, dimethylDNA31 also demonstrates significant bactericidal activity against both persister and stationary-phase Staphylococcus aureus.
mDPR-Val-Cit-PAB-MMAE consists the ADCs linker (mDPR-Val-Cit-PAB) and potent tubulin inhibitor (MMAE), mDPR-Val-Cit-PAB-MMAE is an antibody drug conjugate.
MC-Val-Cit-PAB-vinblastine is a potent antitumor drug-linker conjugate for Antibody-Drug Conjugates (ADC), featuring vinblastine (a microtubule protein inhibitor) connected through the MC-Val-Cit-PAB ADC linker.
MC-Val-Cit-PAB-Retapamulin is a drug-linker conjugate for antibody-drug conjugates (ADC) that exhibits potent antitumor activity. This compound utilizes Retapamulin, a ribosome inhibitor, connected through the ADC linker MC-Val-Cit-PAB.
Fmoc-PEG3-Ala-Ala-Asn(Trt)-PAB is a cleavable three-unit polyethylene glycol (PEG) linker employed in the synthesis of antibody-drug conjugates (ADCs)[1].
Azido-PEG3-Val-Cit-PAB-PNP is a cleavable 3 unit PEG ADC linker employed for synthesizing antibody-drug conjugates (ADCs)[1]. It also serves as a PEG-based PROTAC linker for the synthesis of PROTACs[2].
MC-Sq-Cit-PAB-Gefitinib is a potent antitumor drug-linker conjugate for Antibody-Drug Conjugates (ADC), utilizing Gefitinib—an EGFR tyrosine kinase inhibitor—connected through the MC-Sq-Cit-PAB ADC linker.